GSK chases next biotech asthma drug with $230 million J&J deal
 

GSK chases next biotech asthma drug with $230 million J&J deal
LONDON (Reuters) - GlaxoSmithKline has bought global rights to an experimental drug from Johnson & Johnson for up to 175 million pounds ($230 million), raising its bet on a new generation of biotech medicines for severe asthma.http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...zc:F7zBnMyn0Lo http://feeds.feedburner.com/~ff/reut...zc:V_sGLiPBpWU
http://feeds.feedburner.com/~r/reute...~4/_KghM-BhoQk